Clinical development of mGluR5 Antagonists to treat Fragile X syndrome and Autism
Randall Carpenter, MD, Principal Investigator (2007)
Mark Bear, PhD, Co-Investigator (2007)
FRAXA Awards:
Seaside Therapeutics received a major grant from the NIH, with additional funding from FRAXA and Cure Autism Now (CAN)to develop STX107, a selective mGluR5 antagonist, as a treatment for fragile X.
|